← Research library

Meteoadaptogenic properties of peptide drugs in healthy volunteers

Controlled study in people · 2007

What was studied
127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
Main finding
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

Noopept PWC170 in cold · 189 ± 10 versus 162 ± 2 · Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control

Related evidence maps: Military & occupational ↗

Reported findings and study design

Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.

127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.

Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage

Results · Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
MeasureResultComparison, timing and statistics
Noopept PWC170 in cold189 ± 10 versus 162 ± 2Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 in heat188 ± 6 versus 152 ± 1Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept arithmetic errors in heat0 ± 0 versus 0.8 ± 0.2Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control
Noopept state / trait anxiety in heat27 ± 3 / 27 ± 2Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control
Noopept PWC170 at simulated altitude197 ± 8 versus 154 ± 3Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control
Noopept activity self-rating in heat5.9 ± 0.4 versus 4.2 ± 0.2Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber
Cold chamber (−10°C): selected reported rows
Cold chamber (−10°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5153 ± 71.5 ± 0.0110.5 ± 1.21.2 ± 0.833 ± 331 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 1b155 ± 1b1.5 ± 0.0019.3 ± 1.71.5 ± 0.633 ± 331 ± 45.6 ± 0.45.3 ± 0.35.7 ± 0.5
Before chamberVinpotropil44 ± 3219 ± 9ab1.6 ± 0.01ab10.5 ± 1.02.1 ± 0.935 ± 332 ± 35.1 ± 0.35.0 ± 0.24.8 ± 0.5
Before chamberNoopept46 ± 3189 ± 3ab1.6 ± 0.01ab9.2 ± 1.20.4 ± 0.228 ± 2a27 ± 26.0 ± 0.96.3 ± 0.86.2 ± 0.7
Before chamberDilept42 ± 1b176 ± 1ab1.5 ± 0.0210.8 ± 1.80.8 ± 0.428 ± 2a28 ± 36.2 ± 0.75.4 ± 0.75.8 ± 0.3
Before chamberPlacebo48 ± 2159 ± 31.5 ± 0.019.7 ± 0.71.2 ± 0.631 ± 431 ± 35.6 ± 0.25.2 ± 0.35.6 ± 0.4
In chamberHistorical no-drug control45 ± 5165 ± 71.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin45 ± 3210 ± 7ab1.6 ± 0.02ab11.0 ± 1.90.3 ± 0.3ab38 ± 431 ± 45.2 ± 0.34.7 ± 0.45.1 ± 0.4
In chamberVinpotropil45 ± 2219 ± 13ab1.6 ± 0.02ab7.5 ± 0.8b0.5 ± 0.2ab36 ± 228 ± 3a4.9 ± 0.3b4.9 ± 0.15.1 ± 0.3
In chamberNoopept44 ± 2189 ± 10ab1.6 ± 0.02ab10.6 ± 1.51.6 ± 0.630 ± 3a27 ± 3a5.3 ± 0.36.0 ± 1.1a6.4 ± 0.8
In chamberDilept41 ± 1ab182 ± 5ab1.7 ± 0.01ab10.8 ± 1.90.8 ± 0.4a29 ± 3a28 ± 3a5.9 ± 0.5a5.3 ± 0.3a5.4 ± 0.6
In chamberPlacebo47 ± 2162 ± 21.5 ± 0.0110.0 ± 0.61.2 ± 0.533 ± 332 ± 35.4 ± 0.25.1 ± 0.45.5 ± 0.3

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Heat chamber (+45°C): selected reported rows
Heat chamber (+45°C): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control47 ± 3161 ± 41.5 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin43 ± 2181 ± 5ab1.6 ± 0.01ab11.5 ± 1.60.67 ± 0.235 ± 332 ± 35.1 ± 0.34.9 ± 0.24.8 ± 0.5
Before chamberVinpotropil45 ± 2189 ± 9ab1.6 ± 0.02ab10.7 ± 1.00.9 ± 0.429 ± 326 ± 35.9 ± 0.35.8 ± 0.2ab5.9 ± 0.3
Before chamberNoopept48 ± 3182 ± 3ab1.6 ± 0.01ab9.6 ± 1.30.8 ± 0.428 ± 3a27 ± 36.1 ± 0.2a6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberDilept44 ± 2180 ± 7ab1.6 ± 0.01ab9.7 ± 1.80.7 ± 0.226 ± 3ab28 ± 35.4 ± 0.24.6 ± 0.5b4.9 ± 0.2
Before chamberPlacebo46 ± 2164 ± 21.5 ± 0.0111.0 ± 0.61.0 ± 0.132 ± 330 ± 35.5 ± 0.25.3 ± 0.25.5 ± 0.5
In chamberHistorical no-drug control47 ± 4151 ± 51.5 ± 0.019.8 ± 1.92.5 ± 0.438 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin39 ± 1a155 ± 91.5 ± 0.029.6 ± 1.10.8 ± 0.7a36 ± 228 ± 3a4.9 ± 0.34.9 ± 0.1a5.1 ± 0.3
In chamberVinpotropil41 ± 2a202 ± 11ab1.6 ± 0.02ab10.3 ± 1.10.7 ± 0.4a31 ± 327 ± 3ab5.7 ± 0.2ab5.6 ± 0.2ab5.9 ± 0.3b
In chamberNoopept44 ± 3188 ± 6ab1.6 ± 0.01ab12.0 ± 1.40 ± 0ab27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberDilept42 ± 2174 ± 9ab1.5 ± 0.01ab10.5 ± 0.90.8 ± 0.5a27 ± 3ab28 ± 2ab5.1 ± 0.34.6 ± 0.2a4.9 ± 0.2
In chamberPlacebo42 ± 4152 ± 11.5 ± 0.0110.9 ± 1.30.8 ± 0.234 ± 333 ± 35.3 ± 0.24.9 ± 0.35.3 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Simulated altitude (3,000 m): selected reported rows
Simulated altitude (3,000 m): selected reported rows
SettingPreparationGrip strength, kgPWC170Max oxygen uptake, LArithmetic actionsArithmetic errorsState anxietyTrait anxietyWell-beingActivityMood
Before chamberHistorical no-drug control46 ± 5151 ± 41.3 ± 0.0110.5 ± 1.01.2 ± 0.833 ± 231 ± 45.6 ± 0.34.9 ± 0.25.5 ± 0.5
Before chamberCortexin42 ± 2170 ± 5a1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.1234 ± 332 ± 35.6 ± 0.35.1 ± 0.25.5 ± 0.3
Before chamberVinpotropil46 ± 2195 ± 5ab1.6 ± 0.01ab9.0 ± 0.50.5 ± 0.228 ± 327 ± 36.1 ± 0.2ab6.1 ± 0.3ab6.4 ± 0.3ab
Before chamberNoopept47 ± 3202 ± 3ab1.6 ± 0.01ab11.2 ± 0.60.2 ± 0.229 ± 326 ± 25.9 ± 0.35.8 ± 0.2a5.9 ± 0.3
Before chamberDilept41 ± 1181 ± 3ab1.6 ± 0.01ab14.2 ± 3.01.0 ± 0.627 ± 3a28 ± 26.2 ± 0.2ab5.8 ± 0.1a5.8 ± 0.2
Before chamberPlacebo46 ± 4162 ± 51.5 ± 0.0110.1 ± 0.80.6 ± 0.133 ± 330 ± 35.5 ± 0.25.6 ± 0.25.6 ± 0.4
In chamberHistorical no-drug control46 ± 4145 ± 51.3 ± 0.019.8 ± 1.93 ± 0.638 ± 234 ± 35.0 ± 0.14.2 ± 0.25.4 ± 0.4
In chamberCortexin41 ± 2170 ± 6ab1.6 ± 0.01ab9.7 ± 0.60.2 ± 0.2a34 ± 332 ± 35.4 ± 0.25.0 ± 0.2ab5.4 ± 0.2
In chamberVinpotropil44 ± 2196 ± 6ab1.6 ± 0.01ab10.4 ± 0.90.8 ± 0.3a27 ± 3ab27 ± 2ab6.2 ± 0.3ab5.9 ± 0.4ab6.2 ± 0.2ab
In chamberNoopept45 ± 3197 ± 8ab1.6 ± 0.01ab11.4 ± 1.72.2 ± 2.231 ± 4a27 ± 3ab5.7 ± 0.2a5.6 ± 0.2ab5.9 ± 0.3
In chamberDilept41 ± 1186 ± 6ab1.6 ± 0.01ab12.6 ± 2.50.6 ± 0.4a28 ± 3a28 ± 3ab6.3 ± 0.2ab5.6 ± 0.3ab6.1 ± 0.3ab
In chamberPlacebo46 ± 4154 ± 31.5 ± 0.019.5 ± 1.00.6 ± 0.233 ± 334 ± 35.4 ± 0.34.6 ± 0.15.6 ± 0.2

Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.

Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Random allocation and blinding not established; historical controls and baseline differences limit attribution.
  • Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
  • Experimental intranasal peptide preparations are not equivalent to marketed oral products.
  • No validated protection from heat illness, operational accidents or long-term harm.
  • The Academy report may cover the same participants.

Related publications may describe some of the same participants or experiments.

Source details

Original journal PDF

Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.

Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open

Sources checked

Citation

Clinical trial / comparisonFull text available

P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov. Meteoadaptogenic properties of peptide drugs in healthy volunteers Eksp Klin Farmakol. 70(6):41–47

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards